Vismodegib persistence and discontinuation patterns in Greek patients from a real world setting |
| |
| Authors: | Efthymia Soura Michaela Plaka Vasiliki Chasapi Christina Antoniou Alexander Stratigos |
| |
| Affiliation: | 1. 1st University Department of Dermatology – Venereology, “Andreas Sygros” Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece;2. State Clinic of Dermatology – Venereology, Andreas Sygros Hospital, Athens, Greece |
| |
| Abstract: | Hedghehog pathway inhibitors have been successfully used for patients with locally advanced basal cell carcinomas. However, these treatments have been associated with various adverse events that may limit patient compliance. In this study, an association of patient and disease characteristics with drug compliance in a real clinical setting was made. 18 patients were included in the study. The average patient age was 78.39 years. The time that patients remained to treatment was, on average, 8.73 months. 72.2% of patients experienced at least one adverse event. At study cut‐off, 11 out of 18 patients had discontinued treatment. The most common reason for discontinuation was reported “fatigue” from the treatment due to the type of AEs experienced (37.4%) and patient's choice after complete response achievement (30.8%). Factors that were associated with treatment discontinuation was: number of previous treatments, severity of AEs and patient age. |
| |
| Keywords: | advanced BCC drug persistence vismodegib |
|
|
